Table 1 Baseline characteristics and physiological changes in treated patients

Age, years

–

–

Male gender

–

–

Angiotensin II as first-line agent

–

–

Angiotensin II dose, ng/kg/min

20.0 (8.4–20.8)

20.0 (8.1–20.8)

 High dose catecholamine (> 0.25 μg/kg/min)

–

–

 Receiving catecholamine > 12 h

–

–

 Prone positioning

11 (78.6)

11 (78.6)

 Use of tocilizumab

–

–

 Norepinephrine dose, μg/kg/min

0.02 (0.00–0.09)

0.01 (0.00–0.14)

 Hours using before

–

–

 Systolic arterial pressure, mmHg

110 (105–129)

120 (115–120)

 Diastolic arterial pressure, mmHg

60 (56–64)

70 (59–70)

 Mean arterial pressure, mmHg

77 (76–80)

85 (80–87)

 Heart rate, bpm

72 (68–83)

71 (66–76)

 Atrial fibrillation

–

–

 Cumulative urine output, mL

620.0 (385.0–750.0)

727.0 (470.0–1050.0)

 Oliguria

–

–

 FiO₂

0.50 (0.40–0.60)

0.40 (0.36–0.54)

 PEEP, cmH₂O

12 (10–12)

11 (10–14)

 SpO₂, %

98 (96–98)

97 (91–98)

 PaO₂/FiO₂

195.2 (148.3–245.0)

200.0 (168.0–248.5)

 SpO₂/FiO₂

191.5 (118.4–258.0)

193.8 (142.2–235.9)

 Lactate, mmol/L

1.72 (1.58–2.00)

1.83 (1.53–2.15)

 Creatinine, mg/dL

1.69 (1.16–2.38)

1.69 (1.06–2.43)

 C-reactive protein, mg/dL

202.0 (148.4–231.1)

115.0 (95.0–190.4)

 White blood cell count, × 1000 cells/mm³

10.1 (6.2–12.4)

9.2 (7.2–14.2)

 Lymphocyte count, × 1000 cells/mm³

7.90 (3.70–12.85)

8.30 (5.20–13.50)